Robbins Arroyo LLP is Investigating the Officers and Directors of Osmotica Pharmaceuticals plc (OSMT) on Behalf of Shareholders

Shareholder rights law firm Robbins
Arroyo LLP is investigating whether certain officers and directors
of Osmotica Pharmaceuticals plc (NASDAQ: OSMT) violated federal
securities law. Osmotica is a biopharmaceutical company focused on
developing and commercializing specialty products.

View this press release on the firm's Shareholder Rights Blog: https://www.robbinsarroyo.com/osmotica-pharmaceuticals-plc/

Osmotica’s Preliminary Results Fail to Beat Placebo

On March 27, 2019, after the markets closed, Osmotica announced
preliminary results for a second Phase 3 clinical trial of arbaclofen
extended-release tablets that failed to beat placebo as measured by the
Clinical Global Impression of Change. On this news, shares of Osmotica
fell $2.74, or nearly 41%, to close at $4.00 on March 28, 2019, and has
yet to recover.

Osmotica Shareholders Have Legal Options

Concerned shareholders who would like more information about their
rights and potential remedies can contact attorney Leonid Kandinov at
(800) 350-6003, [email protected],
or via the shareholder
information form on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in shareholder
rights law. The firm represents individual and institutional investors
in shareholder derivative and securities class action lawsuits, and has
helped its clients realize more than $1 billion of value for themselves
and the companies in which they have invested. Sign up for our FREE
portfolio monitoring service, Stock
Watch.

Attorney Advertising. Past results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190412005384/en/